<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19173" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cerebral Amyloid Angiopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kuhn</surname>
            <given-names>James</given-names>
          </name>
          <aff>Aventura Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharman</surname>
            <given-names>Tariq</given-names>
          </name>
          <aff>Southern Ohio Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Kuhn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tariq Sharman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19173.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cerebral amyloid angiopathy is a type of cerebrovascular disorder characterized by the accumulation of amyloid beta-peptide within the leptomeninges and small to medium-sized cerebral blood vessels. This disorder can have severe morbidity and mortality if it is not identified and treated promptly. This activity highlights the role of the interprofessional team in evaluating and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of cerebral amyloid angiopathy.</p></list-item><list-item><p>Review the appropriate evaluation of cerebral amyloid angiopathy.</p></list-item><list-item><p>Outline the management options available for cerebral amyloid angiopathy.</p></list-item><list-item><p>Summarize the importance of the interprofessional team to improve outcomes for patients affected by cerebral amyloid angiopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19173">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19173.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cerebral amyloid angiopathy (CAA) is a type of cerebrovascular disorder characterized by the accumulation of amyloid beta-peptide within the leptomeninges and small/medium-sized cerebral blood vessels.<xref ref-type="bibr" rid="article-19173.r1">[1]</xref>&#x000a0;The amyloid deposition results in fragile vessels that may manifest in lobar intracerebral hemorrhages (ICH). It may also present with cognitive impairments, incidental microbleeds, hemosiderosis, inflammatory leukoencephalopathy, Alzheimer disease, or transient neurological symptoms.<xref ref-type="bibr" rid="article-19173.r2">[2]</xref>&#x000a0;It can occur in certain familial syndromes or can occur sporadically. Diagnosis is primarily made through a combination of clinical, pathological, and radiographic findings. However, a definitive diagnosis requires a postmortem examination of the brain. Currently, there are no disease-modifying treatments available. Prognosis is dependent on CAA presenting features, with worse outcomes in patients with large hematomas and older age.</p>
      </sec>
      <sec id="article-19173.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of cerebral amyloid angiopathy is not fully understood. CAA is characterized by congophilic material (amyloid-beta peptide) being deposited into the leptomeninges and small to medium-sized cerebral blood vessels. This deposition weakens vessel walls, making them prone to bleeding. CAA can occur in certain familial syndromes or can occur sporadically.</p>
        <p>
<bold>Familial CAA</bold>
</p>
        <p>Cases of &#x0201c;presenile&#x0201d; CAA are caused by mutations in the amyloid precursor protein (APP) gene.<xref ref-type="bibr" rid="article-19173.r3">[3]</xref>&#x000a0;Examples of other mutations resulting in familiar CAA&#x000a0;include ACys peptide, ATTR peptide, PrPSc peptide, ABri peptide, ADan peptide, and AGel peptide.</p>
        <p>
<bold>Sporadic CAA</bold>
</p>
        <p>In the older patient population, the factors that result in amyloid beta-peptide deposition are not well understood. Some evidence has demonstrated a relationship with apolipoprotein E (<italic toggle="yes">APOE</italic>). Researchers found that patients with <italic toggle="yes">APOE</italic>&#x000a0;epsilon 2 or epsilon 4 alleles&#x000a0;seem to be at a greater risk for&#x000a0;cranial hemorrhages than the general population.<xref ref-type="bibr" rid="article-19173.r4">[4]</xref></p>
      </sec>
      <sec id="article-19173.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cerebral amyloid angiopathy is strongly age-dependent, with the prevalence of moderate to severe CAA increasing with age. Sporadic CAA uncommonly affects individuals younger than 60 to 65 and even rarer for those in their 50s. CAA does not appear to have a predilection for gender. There is a possible association between hypertension and CAA, but this is disputed between experts.</p>
      </sec>
      <sec id="article-19173.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Cerebral amyloid angiopathy is usually asymptomatic in individuals. However, when symptomatic, the most common clinical manifestation is spontaneous lobar hemorrhage. The location and the size of the hemorrhage largely determine the clinical deficits. Those extending towards the ventricles may cause hemiplegia and decreased consciousness, while smaller hemorrhage may cause more focal deficits, headaches, or seizures. Interestingly, very small hemorrhages may be asymptomatic. The hemorrhage location often reflects the distribution of the amyloid-beta peptide, favoring the cortical vessels. The hemorrhages are more likely to occur in the posterior brain. The cerebellum commonly contains vascular amyloid accumulation (primarily the cerebellar cortex and vermis).&#x000a0;</p>
        <p>Cognitive impairment has also been described as a presenting symptom. Three patterns have been described:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gradual decline - microhemorrhages, lobar lacunas, microinfarcts, ischemic leukoencephalopathy</p>
          </list-item>
          <list-item>
            <p>Step-wise decline - recurrent lobar hemorrhages</p>
          </list-item>
          <list-item>
            <p>Rapidly progressive decline - cerebral amyloid angiopathy-related inflammation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19173.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The Boston criteria are commonly used when evaluating patients for Cerebral amyloid angiopathy. It is a combination of clinical, pathological, and radiographic criteria that are used to assess the probability of CAA. Definitive diagnoses can only be made through a postmortem examination of the brain. However, a &#x0201c;probable CAA&#x0201d; diagnosis can be made during life utilizing imaging or tissue sampling.</p>
        <p>
<bold>Modified Boston Criteria</bold>
</p>
        <p>- Definite CAA (postmortem) &#x02013; postmortem examination demonstrating:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lobar, cortical-subcortical hemorrhage, or cortical hemorrhage</p>
          </list-item>
          <list-item>
            <p>Absence of another diagnostic lesion</p>
          </list-item>
          <list-item>
            <p>Severe CAA with vasculopathy</p>
          </list-item>
        </list>
        <p>- Probable CAA (with pathology)- clinical data and pathologic tissue demonstrating:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lobar, cortical-subcortical hemorrhage, or cortical hemorrhage</p>
          </list-item>
          <list-item>
            <p>Pathological evidence of CAA</p>
          </list-item>
          <list-item>
            <p>Absence of another diagnostic lesion</p>
          </list-item>
        </list>
        <p>- Probable CAA (with imaging) &#x02013; clinical data and imaging demonstrating:</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple hemorrhages restricted to the cortical, lobar, or cortical-subcortical regions or&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Single lobar, cortical, or cortical-subcortical hemorrhage and focal or disseminated&#x000a0;superficial siderosis</p>
          </list-item>
          <list-item>
            <p>Absence of another diagnostic lesion</p>
          </list-item>
          <list-item>
            <p>Age &#x02265;55 years</p>
          </list-item>
        </list>
        <p>- Possible CAA (with imaging) - clinical data and imaging demonstrating:</p>
        <list list-type="bullet">
          <list-item>
            <p>Single hemorrhage restricted to the cortical, lobar, or cortical-subcortical region. Or diffuse, superficial siderosis</p>
          </list-item>
          <list-item>
            <p>Absence of another diagnostic lesion</p>
          </list-item>
          <list-item>
            <p>Age &#x02265;55 years</p>
          </list-item>
        </list>
        <p>
<bold>Imaging</bold>
</p>
        <p>Gradient-echo magnetic resonance imaging (MRI) is one of the most important techniques used for diagnosis. Gradient-echo magnetic resonance imaging (MRI) demonstrates regions of low-signal blooming artifact&#x000a0;caused by iron depositions left by old hemorrhages. Another very useful technique is a susceptibility-weighted MRI (more sensitive than gradient-echo magnetic resonance imaging (MRI)). Using these techniques, multiple areas of hemorrhage can be identified to help support the diagnosis of CAA.<xref ref-type="bibr" rid="article-19173.r5">[5]</xref></p>
        <p>
<bold>Pathology</bold>
</p>
        <p>Brain biopsies are rarely utilized in the diagnosis of CAA, except when CAA-related inflammation is suspected. If a sample is obtained, it should be examined with beta-amyloid immunostain or Congo red stain. Using these techniques, the deposition of amyloid beta-peptide can be identified to help support the diagnosis of CAA.<xref ref-type="bibr" rid="article-19173.r6">[6]</xref></p>
      </sec>
      <sec id="article-19173.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management is often based on presenting symptoms. Acute management of patients with an ICH is similar to other spontaneous ICH. Attention to blood pressure and intracranial pressure is essential. When surgical intervention is performed, the mortality risk is largely unchanged when compared to&#x000a0;other types of ICH. The factors that are associated with a worse prognosis are intraventricular hemorrhage and age greater than equal to 75.</p>
        <p>ICH associated with CAA is frequently recurrent. Because of this high rate, clinicians typically avoid antiplatelet agents and anticoagulants when a strong indication for anticoagulation is not present. Notably, there have been studies&#x000a0;demonstrating benefits in restarting anticoagulation in&#x000a0;patients with atrial fibrillation.<xref ref-type="bibr" rid="article-19173.r7">[7]</xref></p>
        <p>Blood pressure control has also been associated with mortality benefits, even though CAA does not seem to be largely driven by hypertension.<xref ref-type="bibr" rid="article-19173.r8">[8]</xref>&#x000a0;The PROGRESS trial demonstrated a risk reduction of 77% for CAA-related ICH when blood pressure was controlled. The observation supports these findings that lower ambulatory blood pressure resulted in a reduced risk of ICH recurrence.</p>
        <p>Lastly, limited evidence has shown benefits in utilizing immunosuppression for the treatment of the inflammatory forms of CAA. Small trials have shown pulsed cyclophosphamide or glucocorticoids resulted in sustained clinical improvement. Other immunosuppressive medications have also been associated with benefits, including mofetil, mycophenolate, and methotrexate.<xref ref-type="bibr" rid="article-19173.r9">[9]</xref></p>
      </sec>
      <sec id="article-19173.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Nontraumatic ICH includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemorrhagic tumor</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic transformation of an ischemic stroke</p>
          </list-item>
          <list-item>
            <p>Lobar extension of a hypertensive putaminal hemorrhage</p>
          </list-item>
          <list-item>
            <p>Arteriovenous malformation (AVM)</p>
          </list-item>
        </list>
        <p>Other imaging differential diagnosis includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertensive microangiopathy</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic metastases</p>
          </list-item>
          <list-item>
            <p>Multiple cavernoma syndrome</p>
          </list-item>
          <list-item>
            <p>Diffuse axonal injury</p>
          </list-item>
          <list-item>
            <p>Radiation-induced vasculopathy</p>
          </list-item>
          <list-item>
            <p>Neurocysticercosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19173.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of cerebral amyloid angiopathy can be variable but is largely determined by the location and size of the ICH. Unfavorable outcomes are associated with larger hematoma size and the age of the patient (&#x02265;75). Favorable ICH outcomes are associated with sparing of the ventricles and a superficial location. Mortality ranges from 10% to 30%, with the best prognosis seen in patients with increased consciousness and smaller hematomas (&#x0003c;50 mL). CAA has a high hemorrhage recurrence risk when compared to a hypertensive hemorrhage. Studies have revealed recurrence rates of around 21%.<xref ref-type="bibr" rid="article-19173.r10">[10]</xref></p>
        <p>CAA is commonly associated with both transient and cognitive neurological impairment. Transient neurological symptoms are characterized by brief, recurrent spells of numbness, paresthesias, and weakness. The pathogenesis is not fully understood, but symptoms are typically only transient. At the same time, the cognitive impairments have revealed diminished cognitive speed and episodic memory loss. Interestingly, Alzheimer disease and CAA frequently coexist. CAA has also been found to&#x000a0;correlate with vascular dementia.<xref ref-type="bibr" rid="article-19173.r11">[11]</xref></p>
      </sec>
      <sec id="article-19173.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Besides the ICH, Cerebral amyloid angiopathy has many other complications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Transient neurologic symptoms</p>
          </list-item>
          <list-item>
            <p>Microbleeds</p>
          </list-item>
          <list-item>
            <p>Cortical superficial siderosis</p>
          </list-item>
          <list-item>
            <p>CAA-related inflammation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cognitive impairment</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19173.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Cerebral amyloid angiopathy (CAA) is a type of cerebrovascular disorder characterized by the accumulation of amyloid within the leptomeninges and small/medium-sized cerebral blood vessels.<xref ref-type="bibr" rid="article-19173.r1">[1]</xref>&#x000a0;The amyloid deposition results in fragile vessels that may manifest in brain bleeds. It may also present with cognitive impairments, incidental microbleeds, hemosiderosis, inflammatory leukoencephalopathy, Alzheimer's disease, or transient neurological symptoms.<xref ref-type="bibr" rid="article-19173.r2">[2]</xref>&#x000a0;It can occur in certain familial syndromes or sporadically. Diagnosis is primarily made through a combination of clinical, pathological, and radiographic findings. Currently, there are no disease-modifying treatments available. Prognosis is dependent on CAA presenting features, with worse outcomes in patients with large hematomas and older age.</p>
      </sec>
      <sec id="article-19173.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of patients with Cerebral amyloid angiopathy is best when using an interprofessional team that includes primary care doctors, neurosurgeons, radiologists, and pathologists. Stroke-trained nurses, physical therapists, and pharmacists should also assist in the case. The patient most often will present to the emergency department in the setting of stroke symptoms. Utilizing clinical and radiographic findings, the probability of CAA can be assessed. Treatment of ICH is similar to other spontaneous ICH, possibly requiring intervention from neurosurgery. Attention to blood pressure and intracranial pressure by the staff is essential. If there is residual impairment, rehabilitation is essential to regain mobility and function. The pharmacist may manage the pain and help with the appropriate use of antiplatelet agents and anticoagulants. Long-term follow-up is essential to evaluate for reoccurrence and functional status. If CAA is thought to be familial CAA, further workup can be perused in an outpatient setting. Open communication between the interprofessional is essential for improving outcomes.</p>
      </sec>
      <sec id="article-19173.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19173&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19173">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/cerebral-amyloid-angiopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19173">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19173/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19173">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19173.s14">
        <fig id="article-19173.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Disseminated cerebral amyloid angiopathies Contributed by Sunil Munakomi, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG-6077" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19173.s15">
        <title>References</title>
        <ref id="article-19173.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Cerebral amyloid angiopathy in the elderly.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>871</fpage>
            <page-range>871-80</page-range>
            <pub-id pub-id-type="pmid">22190361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charidimou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Werring</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-37</page-range>
            <pub-id pub-id-type="pmid">22056963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Demarchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Rosa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bellotti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marciano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donadei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arbustini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diegoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Genovese</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coverlizza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy.</article-title>
            <source>Ann Neurol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>639</fpage>
            <page-range>639-44</page-range>
            <pub-id pub-id-type="pmid">16178030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charidimou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zonneveld</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kantarci</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shoamanesh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hilal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Boulouis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Pasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biffi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wahlund</surname>
                <given-names>LO</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gurol</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Barkhof</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Rosand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title><italic>APOE</italic> and cortical superficial siderosis in CAA: Meta-analysis and potential mechanisms.</article-title>
            <source>Neurology</source>
            <year>2019</year>
            <month>Jul</month>
            <day>23</day>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>e358</fpage>
            <page-range>e358-e371</page-range>
            <pub-id pub-id-type="pmid">31243071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Batool</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCreary</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lauzon</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Frayne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds.</article-title>
            <source>Stroke</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>10</issue>
            <fpage>2782</fpage>
            <page-range>2782-6</page-range>
            <pub-id pub-id-type="pmid">23920014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Synek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Cerebral amyloid angiopathy related inflammation: three case reports and a review.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-6</page-range>
            <pub-id pub-id-type="pmid">20935328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biffi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Battey</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Ayres</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cortellini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gilson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rost</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rosand</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Warfarin-related intraventricular hemorrhage: imaging and outcome.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Nov</month>
            <day>15</day>
            <volume>77</volume>
            <issue>20</issue>
            <fpage>1840</fpage>
            <page-range>1840-6</page-range>
            <pub-id pub-id-type="pmid">22049204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tzourio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bousser</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>MacMahon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>J</given-names>
              </name>
              <collab>PROGRESS Collaborative Group</collab>
            </person-group>
            <article-title>Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.</article-title>
            <source>Stroke</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>394</fpage>
            <page-range>394-6</page-range>
            <pub-id pub-id-type="pmid">20044530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinnecom</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lev</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wendell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Rosand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frosch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Course of cerebral amyloid angiopathy-related inflammation.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Apr</month>
            <day>24</day>
            <volume>68</volume>
            <issue>17</issue>
            <fpage>1411</fpage>
            <page-range>1411-6</page-range>
            <pub-id pub-id-type="pmid">17452586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muzikansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wisco</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Betensky</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy.</article-title>
            <source>Ann Neurol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>459</fpage>
            <page-range>459-62</page-range>
            <pub-id pub-id-type="pmid">16130107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19173.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arvanitakis</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Leurgans</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cerebral amyloid angiopathy pathology and cognitive domains in older persons.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-7</page-range>
            <pub-id pub-id-type="pmid">21387377</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
